BR112013012671A2 - sequência sinal de polipeptídio, proteína de fusão, vetor de expressão de proteína, método para produzir um polipeptídio, método para preparar um vetor de expressão de proteína, método para aumentar a expressão da proteína e método para aumentar a secreção da proteína - Google Patents
sequência sinal de polipeptídio, proteína de fusão, vetor de expressão de proteína, método para produzir um polipeptídio, método para preparar um vetor de expressão de proteína, método para aumentar a expressão da proteína e método para aumentar a secreção da proteínaInfo
- Publication number
- BR112013012671A2 BR112013012671A2 BR112013012671A BR112013012671A BR112013012671A2 BR 112013012671 A2 BR112013012671 A2 BR 112013012671A2 BR 112013012671 A BR112013012671 A BR 112013012671A BR 112013012671 A BR112013012671 A BR 112013012671A BR 112013012671 A2 BR112013012671 A2 BR 112013012671A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein expression
- protein
- expression vector
- polypeptide
- increasing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41592610P | 2010-11-22 | 2010-11-22 | |
| US61/415,926 | 2010-11-22 | ||
| PCT/US2011/061862 WO2012071422A2 (en) | 2010-11-22 | 2011-11-22 | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013012671A2 true BR112013012671A2 (pt) | 2016-10-11 |
| BR112013012671B1 BR112013012671B1 (pt) | 2022-03-03 |
Family
ID=46146394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013012671-0A BR112013012671B1 (pt) | 2010-11-22 | 2011-11-22 | Sequência sinal de polipeptídio, proteína de fusão e vetor de expressão de proteína |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9279007B2 (pt) |
| EP (2) | EP3461905B1 (pt) |
| JP (1) | JP2014503198A (pt) |
| KR (2) | KR101984318B1 (pt) |
| CN (1) | CN103328649B (pt) |
| BR (1) | BR112013012671B1 (pt) |
| CA (1) | CA2818689C (pt) |
| CY (1) | CY1121049T1 (pt) |
| DK (2) | DK2643468T3 (pt) |
| ES (2) | ES2829199T3 (pt) |
| HR (1) | HRP20181315T1 (pt) |
| HU (1) | HUE039070T2 (pt) |
| LT (1) | LT2643468T (pt) |
| PL (1) | PL2643468T3 (pt) |
| PT (1) | PT2643468T (pt) |
| RS (1) | RS57601B1 (pt) |
| SI (1) | SI2643468T1 (pt) |
| WO (1) | WO2012071422A2 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106574270B (zh) * | 2014-07-03 | 2021-07-13 | 豪夫迈·罗氏有限公司 | 多肽表达系统 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN110809583A (zh) | 2017-06-07 | 2020-02-18 | 瑞泽恩制药公司 | 用于内化酶的组合物和方法 |
| TW201927825A (zh) * | 2017-11-30 | 2019-07-16 | 美商阿米庫斯醫療股份有限公司 | Cdkl5 表現變體和cdkl5 融合蛋白 |
| US10874750B2 (en) * | 2018-04-30 | 2020-12-29 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| BR112021006829A2 (pt) | 2018-10-10 | 2021-07-20 | Amicus Therapeutics, Inc. | composições de polipeptídeos estabilizados com ligações dissulfeto e métodos de uso |
| EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CA3120638A1 (en) * | 2018-12-19 | 2020-06-25 | Versameb Ag | Rna encoding a protein and a signal peptide with a hydrophobic amino-terminal end |
| AU2020235865A1 (en) | 2019-03-08 | 2021-09-23 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| CN114450308A (zh) | 2019-06-12 | 2022-05-06 | 黑曜石疗法公司 | 用于调节性调控的ca2组合物和方法 |
| EP3983537A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN112342247B (zh) * | 2020-11-10 | 2022-03-11 | 江苏科技大学 | 一种提高家蚕细胞表达外源蛋白分泌率的方法 |
| KR20230128001A (ko) | 2020-12-01 | 2023-09-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 엔젤만 증후군의 치료를 위한 조성물 및 이의 용도 |
| WO2023086939A1 (en) | 2021-11-12 | 2023-05-19 | Amicus Therapeutics, Inc. | Compositions and methods for treating mucopolysaccharidosis iiia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4892132B2 (ja) * | 1998-11-24 | 2012-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | ７０ｋＤ熱ショック蛋白による化合物の細胞内標的輸送 |
| JP4834554B2 (ja) * | 2003-11-06 | 2011-12-14 | ジェネンコー・インターナショナル・インク | 糸状菌におけるプロテアーゼ抑制剤及びその変異体の発現 |
| DE602007007923D1 (de) * | 2006-04-11 | 2010-09-02 | Csl Behring Gmbh | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide |
-
2011
- 2011-11-22 DK DK11843849.8T patent/DK2643468T3/en active
- 2011-11-22 CA CA2818689A patent/CA2818689C/en active Active
- 2011-11-22 SI SI201131554T patent/SI2643468T1/sl unknown
- 2011-11-22 ES ES18181451T patent/ES2829199T3/es active Active
- 2011-11-22 EP EP18181451.8A patent/EP3461905B1/en active Active
- 2011-11-22 RS RS20180986A patent/RS57601B1/sr unknown
- 2011-11-22 PL PL11843849T patent/PL2643468T3/pl unknown
- 2011-11-22 US US13/988,946 patent/US9279007B2/en active Active
- 2011-11-22 KR KR1020137016110A patent/KR101984318B1/ko active IP Right Grant
- 2011-11-22 PT PT11843849T patent/PT2643468T/pt unknown
- 2011-11-22 JP JP2013541026A patent/JP2014503198A/ja not_active Withdrawn
- 2011-11-22 EP EP11843849.8A patent/EP2643468B1/en active Active
- 2011-11-22 WO PCT/US2011/061862 patent/WO2012071422A2/en active Application Filing
- 2011-11-22 LT LTEP11843849.8T patent/LT2643468T/lt unknown
- 2011-11-22 KR KR1020197015057A patent/KR20190060888A/ko not_active IP Right Cessation
- 2011-11-22 HU HUE11843849A patent/HUE039070T2/hu unknown
- 2011-11-22 ES ES11843849.8T patent/ES2687415T3/es active Active
- 2011-11-22 DK DK18181451.8T patent/DK3461905T3/da active
- 2011-11-22 CN CN201180065369.5A patent/CN103328649B/zh active Active
- 2011-11-22 BR BR112013012671-0A patent/BR112013012671B1/pt active IP Right Grant
-
2018
- 2018-08-14 HR HRP20181315TT patent/HRP20181315T1/hr unknown
- 2018-09-12 CY CY181100941T patent/CY1121049T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103328649B (zh) | 2016-06-22 |
| EP3461905B1 (en) | 2020-08-05 |
| PT2643468T (pt) | 2018-10-11 |
| SI2643468T1 (sl) | 2018-10-30 |
| KR101984318B1 (ko) | 2019-05-31 |
| KR20130121878A (ko) | 2013-11-06 |
| EP2643468B1 (en) | 2018-07-04 |
| DK3461905T3 (da) | 2020-11-02 |
| CN103328649A (zh) | 2013-09-25 |
| ES2687415T3 (es) | 2018-10-25 |
| PL2643468T3 (pl) | 2018-11-30 |
| CY1121049T1 (el) | 2019-12-11 |
| JP2014503198A (ja) | 2014-02-13 |
| HUE039070T2 (hu) | 2018-12-28 |
| KR20190060888A (ko) | 2019-06-03 |
| ES2829199T3 (es) | 2021-05-31 |
| EP2643468A4 (en) | 2014-12-24 |
| DK2643468T3 (en) | 2018-09-24 |
| WO2012071422A3 (en) | 2012-08-02 |
| EP3461905A1 (en) | 2019-04-03 |
| RS57601B1 (sr) | 2018-11-30 |
| WO2012071422A2 (en) | 2012-05-31 |
| CA2818689A1 (en) | 2012-05-31 |
| US9279007B2 (en) | 2016-03-08 |
| LT2643468T (lt) | 2018-09-10 |
| US20140045216A1 (en) | 2014-02-13 |
| CA2818689C (en) | 2021-09-21 |
| HRP20181315T1 (hr) | 2018-10-19 |
| BR112013012671B1 (pt) | 2022-03-03 |
| EP2643468A2 (en) | 2013-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013012671A2 (pt) | sequência sinal de polipeptídio, proteína de fusão, vetor de expressão de proteína, método para produzir um polipeptídio, método para preparar um vetor de expressão de proteína, método para aumentar a expressão da proteína e método para aumentar a secreção da proteína | |
| EP2774934A4 (en) | POLYPEPTIDE SOLUTION, PROCESS FOR PRODUCING SYNTHETIC POLYPEPTIDE FIBER, AND METHOD FOR REFINING POLYPEPTIDE | |
| EP2709603A4 (en) | MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS AND APPLICATIONS THEREWITH | |
| EP2716798A4 (en) | ARTIFICIAL POLYPEPTIDE FIBER AND PROCESS FOR PRODUCING THE SAME | |
| BRPI1014253A2 (pt) | polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento | |
| BR112012022046A2 (pt) | ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''. | |
| WO2012139134A3 (en) | Methods of modulating oncogenic fusion proteins | |
| BR112014002006A2 (pt) | proteína de fusão, célula engenheirada para expressar a proteína de fusão, vetor, e, método para tratar um paciente com câncer | |
| EP2714732A4 (en) | PROCESS FOR PREPARING FC-CONTAINING POLYPEPTIDES WITH IMPROVED PROPERTIES | |
| PT3321287T (pt) | Proteínas de fusão e vacinas de combinação | |
| DK2794427T4 (da) | Kapsel, kapsellegeme, fremgangsmåde og system til tilberedning af en drik | |
| BRPI0916615A2 (pt) | Construtos e métodos para a produção e secreção de polipeptídeos | |
| EP2711377A4 (en) | FUSION PROTEIN FOR ANTAGONIZING ANGIOGENICALLY INDUCIBLE FACTORS AND USE THEREOF | |
| EP2714065A4 (en) | CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, PROCESS FOR THEIR MANUFACTURE AND USE | |
| EP2924049A4 (en) | TROPHIC HORMONE FUSION PROTEIN, PREPARATION METHOD AND APPLICATION THEREOF | |
| HK1202587A1 (en) | Soluble igf receptor fc fusion proteins and uses thereof igf fc | |
| EP2842969A4 (en) | LACTOFERRIN BASED FUSION PROTEIN AND PROCESS FOR PRODUCING THE SAME | |
| SG10201500208SA (en) | Npp1 fusion proteins | |
| ZA201403189B (en) | Method for preparing physiologically active polypeptide complex | |
| EP2698386B8 (en) | Fusion protein | |
| HK1187369A1 (en) | Fusion protein for secretory protein expression | |
| EP2683742A4 (en) | NPP1 FUSION PROTEIN | |
| IL234683B (en) | Fusion proteins containing toso protein and a method for their production | |
| IL232867B (en) | Amyloid-binding polypeptide and chimeric protein containing it, pharmaceutical preparations containing the polypeptide or chimeric protein, methods for their preparation and uses | |
| PL2714902T3 (pl) | Wektory ekspresyjne do polepszonej sekrecji białka |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: AMICUS THERAPEUTICS, INC. (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/11/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |